Synthesis Characterization and In Vitro Release Study of Ciprofloxacin-Loaded Chitosan Nanoparticle
- 38 Downloads
Ciprofloxacin, a poorly soluble drug-loaded chitosan nanoparticle, was prepared for the treatment of microbial infections. Nanoformulation of ciprofloxacin was prepared using 85% deacetylated chitosan as a biodegradable polymer and tripolyphosphate (TPP) as a cross-linking agent by ionotropic gelation. It was further evaluated and characterized on the basis of morphology, drug loading efficiency, X-ray diffraction, zeta potential value, Fourier transform infrared study, antimicrobial study, and also in vitro release behavior of ciprofloxacin. The FTIR spectral studies indicated that there was no interaction found between the drug and chitosan. The sample CS1 formulation was found stable with good drug entrapment efficiency, fair zeta potential value, and its size ranged between 100 and 200 nm. The in vitro study showed sustained release behavior with steady rise in cumulative drug release (> 99%) for up to about 8 h and thereafter, no significant release observed. The characterized formulations were also used to study antimicrobial activity.
KeywordsNanoformulation Ciprofloxacin Zeta potential Biodegradable polymer Microbial infection
The authors would like to acknowledge the financial support from the Department of Science & Technology-INSPIRE fellowship, New Delhi, India. Prof. R.K.Mandal (Department of Metallurgical Engineering, IIT, BHU, Varanasi) for providing SEM facility, CISF, IIT,BHU for providing XRD facility & S.K. Singh (Department of pharmaceutics, IIT, BHU, VARANASI) for providing zeta potential and FTIR facility.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflicts of interest.
- 2.LG, S., & WN, K. (1997). Development of ciprofloxacin: the USA perspective. In W. APR & R. N. Gruneberg (Eds.), Ciprofloxacin: 10 years of clinical experiences (pp. 1–5). Oxford: Published by Maxim Medical.Google Scholar
- 3.British Pharmacopia (BP). (2009). (493). London: The stationary office; 493.Google Scholar
- 5.Wilhelmus, K. R., Hyndiuk, R. A., Caldwell, D. R., Abshire, R. L., Folkens, A. T., & Godio, L. B. (1993). 0.3% ciprofloxacin ophthalmic ointment in the treatment of bacterial keratitis. The ciprofloxacin ointment/bacterial keratitis study group. Archives of Ophthalmology, 11, 1210–1218.CrossRefGoogle Scholar
- 10.Goya, S., Rai, J. K., Narang, R. K., & Rajesh, K. S. (2010). International Journal of Pharmacy and Pharmaceutical Sciences, 2(2), 1–6.Google Scholar
- 16.Calvo, P., Remuan-Lopez, C., Vila-Jato, J., & Alonso, M. (1997). Journal of Applied Polymer Science, 125132, 63.Google Scholar